California Coal Tar Litigation Stay Sought Pending FDA Petition Review
This article was originally published in The Rose Sheet
Executive Summary
California litigation over the use of coal tar in dandruff shampoos and other OTC drugs should be suspended pending FDA review of the ingredient's safety, drug distributor Bergen Brunswig tells a San Francisco judge.
You may also be interested in...
Coal Tar Cosmetics Use Data To Be Requested By CIR
The Cosmetic Ingredient Review Expert Panel will seek data on concentrations of coal tar use in cosmetics in its review of the OTC ingredient, the panel concurred at a meeting in Washington, D.C. Sept. 10-11
Coal Tar Cosmetics Use Data To Be Requested By CIR
The Cosmetic Ingredient Review Expert Panel will seek data on concentrations of coal tar use in cosmetics in its review of the OTC ingredient, the panel concurred at a meeting in Washington, D.C. Sept. 10-11
Coal tar
California Prop 65 trial over use of coal tar in dandruff shampoos and other OTCs stayed until Jan. 29. Consolidated trial in separate lawsuits brought by the state and Perry Gottesfeld had been slated to begin Oct. 10, but defendants Bergen Brunswig and Reedco requested a stay pending FDA review of the ingredient's safety (1"The Rose Sheet" Sept. 4, p. 7). Defendants include J&J's Neutrogena division and Denorex shampoo marketer Whitehall-Robins. Reedco is a subsidiary of Tegrin maker Block Drug, which SmithKline Beecham is acquiring for roughly $1.24 bil